Inhibition of SGK1 confers vulnerability to redox dysregulation in cervical cancer
Highlights • SGK1 promotes survival of cervical cancer cells through exerting anti-ROS activity. • SGK1 induces NRF2 expression and activity in a c-JUN dependent manner. • Melatonin's pro-oxidant action synergizes with SGK1 inhibition in vitro. • Combined use of SGK1 inhibitor and melatonin demonstrates cervical tumor regression.